- Many Young Men Putting Health at Risk to Bulk Up
- FDA Warns Two Kratom Marketers About False Claims
- Buyer Beware: Many Stem Cell Clinics Lack Docs Trained in Treatments
- Experts Want Doctors to Add Vaping to Youth Prevention Pitch
- Outcomes Poor Years After Radiation for Pediatric Glioma Survivors
- Smoking Confers Greatest Risk for Major Heart Attack for Women
- Anesthesia Tied to Neurocognitive Impairment in Childhood ALL Survivors
Karima Oualla, MD. Dr. Karima Oualla discusses recent advances on the use of checkpoint inhibitors in the treatment of triple negative breast cancer (TNBC). Dr. Oualla is an International expert in breast cancer and is the primary author of the manuscript entitled "Novel therapeutic strategies in the treatment of triple-negative… Robert L. Coleman, MD. Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of… Ted Lain, MD. Clinical trial investigator Dr. Ted Lain comments on the results of the OPAL study, a Phase 2b clinical trial which evaluated the efficacy of a novel topical gel formulation of the antibiotic minocycline (BPX-01) in reducing the number of inflammatory lesions in patients with moderate-to-severe inflammatory,…
Alzheimer’s disease (AD) is the most common cause of dementia in Western countries.
As I understand, this is a great step of development that we can use to save many people from horrible diseases. and i also hope Dr.Lain and your partners…
Times Online / The Sunday Times voted Doctors Lounge as 3rd best ‘Ask an expert’ website.